TOP TEN perturbations for 28937 (Homo sapiens)

Organism: Homo sapiens
Gene: 28937
Selected probe(set): 211645_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 28937 (211645_x_at) across 5392 perturbations tested by GENEVESTIGATOR:

multiple sclerosis study 10 (PP-MS) / cerebrospinal fluid cell sample (mixed neuropathologies)

Relative Expression (log2-ratio):6.881508
Number of Samples:10 / 9
Experimental multiple sclerosis study 10 (PP-MS)
Cerebrospinal fluid (CSF) cell samples from patients with primary progressive multiple sclerosis (PP-MS). Active disease was defined by the presence of any of the following criteria during 6 month prior CSF collection: (1) one or more relapses, (2) change of 0.5 point or greater in EDSS (Expanded Disability Status Score), (3) change in the number and size of lesions visualized by gadolinium-enhanced MRI. Untreated MS patients did not receive any medication for at least 1 year before CSF sample collection.
Control cerebrospinal fluid cell sample (mixed neuropathologies)
Cerebrospinal fluid (CSF) cell samples from patients with different neuropathologies, other than multiple sclerosis.

osteoarthritis study 4 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-6.3926315
Number of Samples:5 / 6
Experimental osteoarthritis study 4
Synovial tissue biopsy from a swollen knee of patients with osteoarthritis (active disease). Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

microcrystalline arthritis study 1 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-5.8637
Number of Samples:4 / 6
Experimental microcrystalline arthritis study 1
Synovial tissue biopsy from a swollen knee of patients with microcristalline arthritis (active disease). The diagnosis of microcrystalline arthritis was based on the identification of urate or calcium pyrophosphate crystals in the synovial fluid. Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

rheumatoid arthritis study 1 / normal synovial membrane tissue

Relative Expression (log2-ratio):5.6793823
Number of Samples:5 / 6
Experimental rheumatoid arthritis study 1
Synovial membrane tissue from patients with rheumatoid arthritis.
Control normal synovial membrane tissue
Normal synovial membrane tissue.

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):5.347851
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

HCV-related HCC study 1 / adjacent HCV-related liver tissue (LC)

Relative Expression (log2-ratio):-5.310877
Number of Samples:5 / 4
Experimental HCV-related HCC study 1
Hepatitis C infection related human hepatocellular carcinoma sample.
Control adjacent HCV-related liver tissue (LC)
Histologically normal adjacent liver tissue of a patient with Hepatitis C infection related hepatocellular carcinoma. Patient with liver cirrhosis.

seronegative arthritis study 1 / rheumatoid arthritis study 2

Relative Expression (log2-ratio):-5.228035
Number of Samples:4 / 6
Experimental seronegative arthritis study 1
Synovial tissue biopsy from a swollen knee of patients with seronegative arthritis (active disease). The diagnosis of seronegative arthritis was based on the presence of psoriasis or x-ray evidence of sacro-iliacal joint involvement. Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control rheumatoid arthritis study 2
Synovial tissues from rheumatoid arthritis patients.

B-CLL study 9 (CD19+; CD5+; Wnt3a) / Wnt3a study 1

Relative Expression (log2-ratio):-5.221096
Number of Samples:6 / 4
Experimental B-CLL study 9 (CD19+; CD5+; Wnt3a)
CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control Wnt3a study 1
CD19+ B-cell samples from normal control subjects and treated with Wnt3a for 48 hours. It is not clear whether the concentration of Wnt3a was 5ng/ml or 50ng/ml. B-cells were isolated from peripheral blood mononuclear cells and cultured in B-cell media.

osteoarthritis study 4 / lupus arthritis study 1

Relative Expression (log2-ratio):-5.0784645
Number of Samples:5 / 4
Experimental osteoarthritis study 4
Synovial tissue biopsy from a swollen knee of patients with osteoarthritis (active disease). Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).
Control lupus arthritis study 1
Synovial tissue biopsy from a swollen knee of patients with systemic lupus erythematosus (SLE) associated arthritis (active disease). All patients with SLE met the American College of Rheumatology (ACR) revised classification criteria for SLE. Patients were naive to any immunosuppressive therapy, only some of them were receiving nonsteroidal antiinflammatory drugs (NSAID).

B-CLL study 9 (CD19+; CD5+; untreated) / untreated normal B-cell sample (CD19+)

Relative Expression (log2-ratio):-4.959388
Number of Samples:3 / 2
Experimental B-CLL study 9 (CD19+; CD5+; untreated)
Untreated CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control untreated normal B-cell sample (CD19+)
Untreated CD19+ B-cell samples from normal control subjects and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells.